Latest Conference Articles

April 21st 2017, 1:40am

International Liver Congress

MicroRNA-34a, one of the most documented tumor suppressor microRNAs, is being evaluated as a potential therapeutic target in hepatocellular carcinoma.

April 21st 2017, 1:05am

International Liver Congress

Higher levels of hepatocytes positive for pERK immunostaining and greater microvascular invasion have emerged as independent prognostic factors of recurrence in patients following sorafenib (Nexavar) treatment for hepatocellular carcinoma.

April 20th 2017, 6:48pm

International Liver Congress

Nadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the potential for immunotherapy in advanced hepatocellular carcinoma.

April 20th 2017, 6:40pm

International Liver Congress

Amira Abdelhamid, assistant lecturer, German University in Cairo, discusses microRNA-34a and natural killer (NK) cells in hepatocellular carcinoma (HCC).

April 20th 2017, 5:34pm

International Liver Congress

A meta-analysis found that patients were at no elevated risk of developing hepatocellular carcinoma after achieving sustained virologic response following treatment with direct-acting antiviral therapy for hepatitis C compared to interferon therapy.

April 5th 2017, 8:12pm

AACR Annual Meeting

Martin Dreyling, MD, associate professor, University of Munich, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma, during the AACR Annual Meeting.

April 5th 2017, 3:04am

AACR Annual Meeting

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses weighing the overall survival (OS) benefit with the increased risk of toxicities seen with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced melanoma.

April 4th 2017, 11:22pm

AACR Annual Meeting

Adding the IDO inhibitor indoximod to pembrolizumab led to an overall response rate of 52% in patients with advanced melanoma, according to findings from a phase II trial reported at the 2017 AACR Annual Meeting.

April 4th 2017, 11:05pm

AACR Annual Meeting

The IDO1 inhibitor BMS-986205 had "best-in-class" activity as demonstrated by kynurenine reductions and IDO1 inhibition for patients with advanced malignancies in a phase I/IIa study, according to lead investigator Lillian L. Siu, MD, at the 2017 AACR Annual Meeting.

April 4th 2017, 10:52pm

AACR Annual Meeting

Adding a formulation of the Coxsackievirus A21 (CAVATAK®) to ipilimumab (Yervoy) yielded an overall response rate of 50% and was well-tolerated in immunotherapy-naïve and pretreated patients with advanced melanoma.

April 4th 2017, 10:20pm

AACR Annual Meeting

A phase II basket trial has been announced to test that mutations in isocitrate dehydrogenase 1 and 2 are not driver mutations that should be targeted with direct IDH inhibitors, but instead they create vulnerabilities that can be exploited through treatment with PARP inhibitors.

April 4th 2017, 8:16pm

AACR Annual Meeting

Treatment with the RAF dimer inhibitor BGB-283 led to clinical benefit for patients with BRAF V600-mutated melanoma, papillary thyroid cancer, and ovarian cancer.

April 4th 2017, 7:40pm

AACR Annual Meeting

Results of a phase II trial showed that more than 80% of patients with refractory non-Hodgkin lymphoma achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.

April 4th 2017, 2:22am

AACR Annual Meeting

Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses 5-year follow-up data from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC).

April 3rd 2017, 11:46pm

ACCC Annual Meeting, CANCERSCAPE

Jacob Gersh, PhD, lead physicist at the Gibbs Cancer Center & Research Institute, discusses the CyberKnife.

April 3rd 2017, 11:35pm

ACCC Annual Meeting, CANCERSCAPE

Kavita Patel, MD, MS, policy analyst, Brookings Institution, discusses the Cancer Drug Coverage Parity Act.

April 3rd 2017, 9:49pm

AACR Annual Meeting

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the controversy surrounding the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced melanoma, which was explored in the CheckMate-067 trial, during the AACR Annual Meeting.

April 3rd 2017, 9:47pm

AACR Annual Meeting

Long-term survival in patients with metastatic non–small cell lung cancer who received the immune checkpoint inhibitor nivolumab (Opdivo) has proven to be much higher than expected, with 16% of these patients surviving after 5 years, equivalent to about 4 times what would be expected with chemotherapy.

April 3rd 2017, 9:24pm

AACR Annual Meeting

The PD-1 and CTLA-4 inhibitor combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was associated with a 12% reduction in the risk of death versus nivolumab monotherapy in patients with treatment-naïve advanced melanoma.

April 3rd 2017, 9:03pm

AACR Annual Meeting

Treatment with the PD-L1 inhibitor avelumab induced an objective response rate of 33% in patients with advanced Merkel cell carcinoma in the phase II JAVELIN Merkel 200 study, including 2 additional complete responses since the primary analysis.